Physician profile
Anna Balaban
NPI 1750917076
$3,777.37
in general payments reported to CMS, 2019-2025
33 companies · $1,241 in 2025
The $1,241 reported for 2025 was more than what 88% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $543 · 2022: $100 · 2023: $287 · 2024: $1,606 · 2025: $1,241.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,135.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,134.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $626.86 | 2021-2025 | Enhertu, Datroway, Lynparza |
| Daiichi Sankyo INC. | $300.32 | 2024-2025 | Enhertu, Vanflyta |
| Incyte Corporation | $274.12 | 2021-2025 | Monjuvi, Jakafi, Zynyz |
| E.R. Squibb & Sons, L.L.C. | $250.57 | 2021-2024 | Eliquis |
| Genentech, INC. | $227.25 | 2024 | Columvi |
| Gilead Sciences, INC. | $193.28 | 2024-2025 | Trodelvy |
| Celgene Corporation | $188.04 | 2021-2025 | Reblozyl |
| Novartis Pharmaceuticals Corporation | $171.30 | 2023-2025 | |
| Karyopharm Therapeutics INC. | $157.45 | 2023-2024 | Xpovio |
| Sobi, INC | $132.63 | 2023-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $129.63 | 2022-2024 | |
| Pfizer INC. | $119.90 | 2023-2025 | |
| Genentech USA, INC. | $119.43 | 2024-2025 | Tecentriq, Alecensa, Venclexta |
| Dova Pharmaceuticals | $119.30 | 2021 | |
| Genzyme Corporation | $97.56 | 2024-2025 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, INC. | $76.70 | 2021 | |
| Tersera Therapeutics LLC | $68.74 | 2025 | Zoladex |
| Merck Sharp & Dohme LLC | $56.43 | 2025 | Keytruda, Welireg, Lynparza |
| Abbvie INC. | $50.08 | 2024-2025 | |
| Janssen Biotech, INC. | $49.20 | 2025 | Erleada, Talvey, Darzalex |
| Exelixis INC. | $48.36 | 2025 | Cabometyx |
| Array Biopharma INC | $46.09 | 2024-2025 | Braftovi, Tukysa, Mektovi |
| Lilly USA, LLC | $42.04 | 2024-2025 | Verzenio, Jaypirca, Retevmo |
| Alexion Pharmaceuticals, INC. | $41.06 | 2024-2025 | Ultomiris |
| Adc Therapeutics America, INC. | $33.89 | 2025 | |
| Puma Biotechnology, INC. | $25.26 | 2024 | |
| Coherus Oncology, INC. | $22.86 | 2024 | |
| Beigene USA, INC. | $21.60 | 2024 | Brukinsa |
| Eisai INC. | $21.43 | 2025 | |
| Pharmacosmos Therapeutics INC. | $20.04 | 2024 | Cosela |
| Tempus Ai, INC | $16.48 | 2025 | Xt Cdx |
| Novocure INC. | $15.00 | 2025 | Optune Lua (Novottf-200t) |
| Alnylam Pharmaceuticals INC. | $14.47 | 2025 | Givlaari |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Balaban listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.